Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) reported Q2 2017 earnings this Afternoon, coming in at ($1.48) per share, beating Wall Street’s estimates of ($1.54) per Share. Revenue for the quarter came in at $0.68 million missing the streets estimates
Analyst Coverage For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
These are 1 Hold Rating, 9 Buy Ratings .
The current consensus rating for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) is Buy (Score: 2.90) with a consensus target price of $39.40 , a potential (328.26% upside)Recent Insider Trading for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
- On 7/18/2017 Stephen M Dow, Director, bought 25,000 with an average share price of $10.00 per share and the total transaction amounting to $250,000.00.
- On 6/20/2017 Jeffrey T L Smith, VP, sold 585 with an average share price of $20.00 per share and the total transaction amounting to $11,700.00.
- On 1/18/2017 Mark James Litton, Insider, sold 1,498 with an average share price of $23.10 per share and the total transaction amounting to $34,603.80.
- On 1/9/2017 Mark James Litton, Insider, sold 9,516 with an average share price of $23.01 per share and the total transaction amounting to $218,963.16.
- On 12/1/2016 Jeffrey T. L. Smith, VP, sold 3,000 with an average share price of $22.78 per share and the total transaction amounting to $68,340.00.
- On 12/1/2016 John A. Latham, Insider, sold 3,636 with an average share price of $22.78 per share and the total transaction amounting to $82,828.08.
Recent Trading for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Shares of Alder BioPharmaceuticals, Inc. closed the previous trading session at 9.20 down -0.25 -2.65% with 1,104,766 shares trading hands.